PathAI

AI Healthcare Tools AI Research & Education Tools

↳AI Medical Imaging & Diagnostics ↳AI Medical Research & Clinical Decision Support

Enterprise

AI-powered digital pathology platform for oncology diagnostics and biopharma R&D — now part of Roche

Not yet rated

Released 2016

Visit Website

Gallery

4 items

VIDEO

About PathAI

PathAI is a pioneering AI-powered pathology platform founded in 2016 in Boston, dedicated to improving patient outcomes through computational analysis of tissue samples. Now operating under Roche following its May 2026 acquisition ($750M upfront + $300M milestones), PathAI combines its AISight digital pathology platform, 20+ AI algorithms, and CLIA-certified lab services to transform both clinical diagnostics and biopharma drug development.

PathAI's models are trained on over 32.5 million expert annotations from a network of 450+ pathologists — one of the largest annotated pathology training datasets in existence. Its AI algorithms automate complex tasks like HER2 scoring (AIM-HER2), tumor microenvironment characterization (PathExplore), and NASH/MAFLD liver disease grading, enabling pathologists to work faster and with greater consistency. The AISight platform provides scanner-neutral whole slide image management, AI application integration, and collaboration tools for labs and research teams.

PathAI serves hospital pathology labs, academic medical centers, and major pharma companies (including Bristol-Myers Squibb and Merck) needing AI-powered tissue analysis for clinical diagnostics, companion diagnostic development, and biopharma clinical trial support — now with the global scale and infrastructure of Roche behind it.

Key Features

AISight — cloud-native digital pathology image management, analysis, and collaboration platform
20+ FDA-cleared and research-grade AI algorithms for oncology and liver disease
32.5M+ expert pathologist annotations — one of the largest training datasets in pathology AI
AIM-HER2 Breast Cancer algorithm for automated HER2 scoring with aMIL heatmaps
PathExplore panel of human interpretable features (HIFs) for tumor microenvironment research
Companion diagnostics development in partnership with major pharma companies
CLIA-certified lab services for biopharma clinical trial tissue analysis
Whole slide image (WSI) management with scanner-neutral compatibility
Acquired by Roche in May 2026 — now backed by global diagnostic infrastructure
Partnerships with Moffitt Cancer Center, University Hospital Zurich, Bristol-Myers Squibb, and Merck

Pros

Acquired by Roche (May 2026) — now backed by the world's largest diagnostics company
32.5M+ expert annotations — one of the world's largest pathology AI training datasets
20+ AI algorithms covering oncology, liver disease, and tumor microenvironment analysis
AISight is scanner-neutral — works with Leica, Hamamatsu, Philips scanners with FDA clearance
CLIA-certified lab services for biopharma clinical trial support
Partnerships with BMS, Merck, Moffitt Cancer Center, and University Hospital Zurich
First AI pathology company recognized as a leader in CB Insights Digital Pathology market map

Cons

Acquired by Roche in May 2026 — future product roadmap and independent operations may change
Enterprise and biopharma-focused — not accessible to independent pathologists or small labs
No self-serve pricing or trial — all engagements are through enterprise procurement
Requires digital pathology infrastructure (scanners, storage, LIS integration)
Integration complexity for labs not yet on digital pathology workflows

Pricing

PathAI operates exclusively on enterprise contracts with hospitals, pathology labs, and biopharma companies — there is no published pricing or self-serve access. Following its acquisition by Roche in May 2026, PathAI's commercial and contract terms are managed through Roche's diagnostics division.

Clinical lab engagements use AISight for digital pathology workflow integration and AI algorithm deployment. Biopharma partnerships are structured as research service contracts for clinical trial tissue analysis, biomarker discovery, and companion diagnostic development.

Contact PathAI or Roche Diagnostics to explore enterprise and research partnership options.

Claim Verified Creator Badge

Are you the founder of PathAI? Display this listing's verified badge on your website to show your customers that your product has been vetted and listed on AI Central Resources.

HTML Embed Code

<a href="https://www.aicentralresources.com/tool/pathai" target="_blank" rel="noopener">
  <img src="https://www.aicentralresources.com/badges/featured-badge-dark.svg" alt="Featured on AICentralResources" width="200" height="54" style="border: none;" />
</a>

* Place this HTML snippet in your website's footer, landing page, or press section. This creates a search-friendly backlink directly to your verification page.

Connect with PathAI

X (Twitter)LinkedIn

Frequently Asked Questions

PathAI was acquired by Roche in May 2026 for $750 million upfront plus up to $300 million in milestone payments. PathAI now operates as part of Roche's global diagnostics division, with its AISight platform and AI algorithms continuing to expand under Roche's infrastructure.

AISight is PathAI's cloud-native digital pathology image management system. It enables pathology labs and hospitals to manage, view, analyze, and collaborate on whole slide images, while integrating AI algorithms for automated tissue analysis and diagnostic support.

PathAI's AI models were trained on over 32.5 million annotations from a network of 450+ expert pathologists, covering oncology, liver disease, and other complex tissue types. This is one of the largest annotated pathology training datasets in the world.

PathAI serves both clinical diagnostics (hospital pathology labs, reference labs) and biopharma R&D (biomarker discovery, companion diagnostics, clinical trial tissue analysis). It is used by major pharma companies to accelerate drug development with AI-powered tissue analysis.

PathAI supports applications in oncology (breast, prostate, lung, colorectal, and other cancers), liver disease (NASH/MAFLD grading and staging), immunology, and general pathology workflow digitization.